Loading patent…
OwnerGeorge R. Painter, JR., Ernest Randall Lanier +3inventors
InventorsGeorge R. Painter, JR., Ernest Randall Lanier, Dorothy Margolskee, Gwendolyn Powell Painter, Roy Ware
Estimating the term…
The present application provides methods and compositions for treatment or reducing risk of dsDNA virus infection in post-hematopoietic cell transplant (HCT or HSCT) patients. This application also provides methods and composition for reducing the incidence of BK virus associated hematuria and/or renal impairment. The invention also relates to a method of lowering BK viral load in post-hematopoietic cell transplant (HCT or HSCT) patients with HDP-CDV (HDP-CDV) or compound of Formula II, or a pharmaceutically acceptable salt thereof, thereby delaying onset of or reducing risk of end organ disease in these patients.
A method of delaying onset, reducing risk, or treating end-organ damage or impairment in a subject infected with BK virus, the method comprising orally administering to the subject a pharmaceutical composition comprising a therapeutically effective dose of a compound selected from:
A method of reducing incidence of hematuria or renal impairment in a subject at risk of BK virus infection reactivation, the method comprising orally administering to the subject a pharmaceutical composition comprising a therapeutically effective dose of a compound selected from:
A method of slowing or reducing the spread of VZV in a subject in need thereof, said method comprising orally administering to said subject a pharmaceutical composition comprising a therapeutically effective dose of a compound selected from:
Dependencies are inferred from the claim text.